Pharvaris
Tracked across 3 events · 22 articles · First seen May 29, 2026 · Last active Jul 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Pharvaris is the biopharmaceutical company presenting clinical data for its drug deucrictibant at the EAACI Annual Congress 2026, which could positively impact its stock price and market position.
May 29, 2026 · 8 articles
Business
Impact: Pharvaris announced its annual general meeting of shareholders, which is a routine corporate governance event for the company.
Jun 11, 2026 · 8 articles
Business
Impact: Pharvaris' New Drug Application for deucrictibant IR has been accepted by the United States — Food and Drug Administration for the on-demand treatment of Hereditary Angioedema attacks, marking a significant milestone for the company and its potential to launch a new therapy. This acceptance validates years of research and development, positioning Pharvaris for potential commercial success if the drug is approved.
Jul 06, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Pharvaris live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard